Literature DB >> 26809453

The MOGE(S) classification : A TNM-like classification for cardiomyopathies.

E Şahan1, S Şahan2, M Karamanlıoğlu3, M Gul4, O Tufekcioğlu2.   

Abstract

Cardiomyopathy is a disease of the heart muscle resulting from genetic defects, cardiac myocyte injury, or infiltration of the myocardium. Cardiomyopathies are traditionally defined as dilated, restrictive, and hypertrophic cardiomyopathy. Today, the genetic basis of most diseases has been clearly defined and has influenced the approach to familial diseases such as cardiomyopathies. Traditional definitions of cardiomyopathies, such as those by the American Heart Association and the European Society of Cardiology, do not consider the genetic basis of cardiomyopathies. In 2013, the World Heart Federation added the genetic basis of cardiomyopathies and proposed a descriptive genotype-phenotype nosology system termed "MOGE(S)." The MOGE(S) system resembles the TNM classification system for malignancy, and therefore it can be useful for the diagnosis, management, and treatment of cardiomyopathies in a similar manner to cancer management.

Entities:  

Keywords:  Cardiomyopathy; Classification; Genetics; MOGES; Myocardium

Mesh:

Substances:

Year:  2016        PMID: 26809453     DOI: 10.1007/s00059-015-4394-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  23 in total

Review 1.  The molecular genetics of hypertrophic cardiomyopathy: prognostic implications.

Authors:  P Sorajja; P M Elliott; W J McKenna
Journal:  Europace       Date:  2000-01       Impact factor: 5.214

Review 2.  The cardiomyopathies.

Authors:  J F Goodwin; C M Oakley
Journal:  Br Heart J       Date:  1972-06

3.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

4.  Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations.

Authors:  Pernilla von Nandelstadh; Rabah Soliymani; Marc Baumann; Olli Carpen
Journal:  Biochem J       Date:  2011-05-15       Impact factor: 3.857

5.  Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects.

Authors:  Marta Diegoli; Maurizia Grasso; Valentina Favalli; Alessandra Serio; Fabiana Isabella Gambarin; Catherine Klersy; Michele Pasotti; Emanuela Agozzino; Laura Scelsi; Alessandra Ferlini; Oreste Febo; Giovanni Piccolo; Luigi Tavazzi; Jagat Narula; Eloisa Arbustini
Journal:  J Am Coll Cardiol       Date:  2011-08-23       Impact factor: 24.094

6.  Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis.

Authors:  Harriet P Lo; Sandra T Cooper; Frances J Evesson; Jane T Seto; Maria Chiotis; Valerie Tay; Alison G Compton; Anita G Cairns; Alistair Corbett; Daniel G MacArthur; Nan Yang; Katrina Reardon; Kathryn N North
Journal:  Neuromuscul Disord       Date:  2007-09-25       Impact factor: 4.296

7.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

8.  Myoglobinuria as first clinical sign of a primary alpha-sarcoglycanopathy.

Authors:  Ferdinando Ceravolo; Sonia Messina; Carmelo Rodolico; Pietro Strisciuglio; Daniela Concolino
Journal:  Eur J Pediatr       Date:  2013-08-30       Impact factor: 3.183

9.  Long-term outcome and risk stratification in dilated cardiolaminopathies.

Authors:  Michele Pasotti; Catherine Klersy; Andrea Pilotto; Nicola Marziliano; Claudio Rapezzi; Alessandra Serio; Savina Mannarino; Fabiana Gambarin; Valentina Favalli; Maurizia Grasso; Manuela Agozzino; Carlo Campana; Antonello Gavazzi; Oreste Febo; Massimiliano Marini; Maurizio Landolina; Andrea Mortara; Giovanni Piccolo; Mario Viganò; Luigi Tavazzi; Eloisa Arbustini
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

10.  Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study.

Authors:  Kristl G Claeys; Peter F M van der Ven; Anthony Behin; Tanya Stojkovic; Bruno Eymard; Odile Dubourg; Pascal Laforêt; Georgine Faulkner; Pascale Richard; Patrick Vicart; Norma B Romero; Gisela Stoltenburg; Bjarne Udd; Michel Fardeau; Thomas Voit; Dieter O Fürst
Journal:  Acta Neuropathol       Date:  2009-01-17       Impact factor: 17.088

View more
  1 in total

1.  Genetic mutation of familial dilated cardiomyopathy based on next‑generation semiconductor sequencing.

Authors:  Xin-Fu Lin; Jie-Wei Luo; Gui Liu; Yao-Bin Zhu; Zhao Jin; Xing Lin
Journal:  Mol Med Rep       Date:  2018-09-05       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.